JP2010159285A - Nicotine antagonist for neuropsychiatric disorder - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide novel therapy for patients suffering from nicotine-responsive neuropsychiatric disorders. <P>SOLUTION: Nicotine-responsive neuropsychiatric disorders can be treated by administering a nicotine antagonist, particularly mecamylamine. Combination therapy of mecamylamine with a neuroleptic drug is also disclosed. The neuropsychiatric disorders comprises Tourette syndrome, schizophrenia, depression, manic depression, tremors, attention deficit hyperactivity disorder, obsessive-compulsive disorder, hemidystonia, rage outbursts and tardive dyskinesia. <P>COPYRIGHT: (C)2010,JPO&INPIT

Description

  The present invention relates to pharmacological treatment of nicotine-responsive neuropsychiatric diseases, and to treatment by administering a nicotine antagonist (particularly mecamylamine) alone or in combination with a neuroleptic agent. Examples of such diseases include schizophrenia, manic depression (bipolar disorder), obsessive-compulsive disorder, attention deficit polymotor disease, Tourette's syndrome and other movement disorders.

  Tourett's Syndrome (TS) is an autosomal dominant neuropsychiatric disorder characterized by symptoms including multiple movements and phonetic tics. This is a polymotor disorder that usually presents with sudden, rapid, short-term, recurrent, aperiodic, stereotypic movement (motor tic disorder) or voice (phonic tic disorder) Although it is an unavoidable impulse, it can be suppressed for a certain period of time (Non-patent Document 1). In general, motor tics include blinking, involuntary movements of the head, shrugging, distorting the face, etc., while phonic tics include coughing, sniffing, sharp screaming, and tongue screaming , And proverbs. These symptoms generally start in early childhood and vary from those that are relatively alleviated throughout life to those that become very severe (Non-Patent Document 2). Also. Many TS patients exhibit other neuropsychiatric abnormalities including obsessive-compulsive syndrome (Non-Patent Document 3), hyperactivity and attention deficit (Non-Patent Document 4). Problems due to intense temperament or aggressive behavior are also frequently seen (Non-Patent Documents 5 and 6), causing school refusal and learning failure (Non-Patent Documents 7 and 8).

  Although the pathogen of TS has not yet been clarified, it has been suggested that dopamine receptor antagonists and / or dopamine receptor hypersensitization have been suggested because of the therapeutic effects obtained by dopamine receptor antagonists ( Non-patent document 9). Treatment of TS is often performed with dopamine antagonist haloperidol (trade name Haldol, McNeil Pharmaceutical (Raritan, NJ)), in approximately 70% of cases It is effective (Non-Patent Documents 10 and 11). Examples of other neuroleptic agents include pimozide (Non-patent document 12), fluphenazine (Non-patent document 13), and risperidone (Non-patent document 14). Another commonly used drug is the alpha adrenergic antagonist clonidine, which is effective for attention deficit hyperactivity disorder (ADHA), but only 40% effective for motility and phonetic tics (Non-Patent Documents 15 and 16). In addition, clonazepam (Non-patent document 17), naloxone (Non-patent document 18) and fluoxetine (Non-patent document 19) are used as drugs having various degrees of effectiveness. One of the most commonly used drugs is haloperidol (20). However, therapeutic doses of haloperidol often have side effects that prevent continued use, such as lack of concentration, nap status, mania, weight gain, Parkinsonian symptoms, etc. Onset of movement disorder appears (Non-Patent Documents 21 and 22). The side effects of movement disorders are particularly difficult to deal with because of the additional abnormal involuntary movements of the tongue, jaw, torso and / or extremities.

  Because of these side effects, Erenberg and colleagues state that the use of haloperidol or other neuroleptic drugs should be discontinued in most TS patients by the age of 16 (Non-patent Document 23). Side effects make it difficult to control conversations and exercises after TS patients stop taking drugs because of side effects, and they deprive them of many full-time occupations. Among the general public, including law enforcement officers, this syndrome is often considered an addiction. Unexpected movements and proverbs cause major social obstacles.

  It has been shown that systemic or intracaudal administration of nicotine greatly enhances reserpine-induced catalepsy in rats (Non-patent Documents 24 and 25). Follow-up experiments have shown that low doses of nicotine also enhance haloperidol-induced catalepsy (Non-Patent Documents 26-28). Based on these preclinical findings, nicotine may also enhance the therapeutic effects of neuroleptics used to treat hyperkinetic behaviors such as TS.

  In a preliminary clinical trial, 10 TS patients were subsequently prescribed haloperidol and the nicotine chewing gum (2 mg) under the brand name Nicolet. The patient had rapid, significant and obvious improvements from tic and other TS syndromes, which were not well controlled by haloperidol alone (29). In two subsequent experiments, nicotine gum alleviated tic disorders in patients who had already been administered haloperidol, but no effect was seen with placebo gum (Non-Patent Documents 30 and 31). However, the duration of the effect of gum is short (1 to 4 hours), and it is difficult to observe the dosage due to bitterness and side effects on the gastrointestinal tract (Non-patent Document 31).

  For 11 TS patients who did not get a sufficient response to neuroleptic treatment, we tried using a 7 mg, 24-hour transdermal nicotine patch (trade name: Nicoderm TNP) (Non-patent Document 32). ). The patient's tic disorder was videotaped before treatment and 3 hours after the start of treatment. At 3 hours, the frequency and severity of tics decreased by 47% and 34%, respectively. Patients who had little control with neuroleptic treatment showed a more dramatic improvement than those who were effective with neuroleptic drugs alone. The effect of TNP lasted longer than expected 24 hours. In two patients who had suppressed TS syndrome prior to TNP administration, the effect persisted for 3 to 4 months without further nicotine administration.

  To further investigate the effective therapeutic response to TS patients, 20 TS patients, 17 infants and adolescents, 3 adults (18 of them were neuroleptics and tic disorder could not be adequately controlled, After 2 doses of TNP (2 had no drug administration experience), the course was followed over various periods (Non-patent Documents 33 and 34). Responses varied considerably between individuals, but with a single dose of TNP, a significant decrease in the mean value of the Yale Global Tic Severity Scale persists for about 1 to 2 weeks. I understood. Therefore, transdermal nicotine is an effective adjuvant for TS neuroleptic treatment and was effective for two patients even when administered alone.

  50% of children with TS also have attention deficit hyperactivity disorder (ADHD). ADHD is a neurobiological disorder characterized by lack of attention, increased impulsive behavior, and multiple movements. ADHD is currently the most commonly diagnosed childhood neuropsychiatric condition, affecting approximately 3.5 million people is doing. In addition, 60% of adolescents with ADHD are symptomatic even in adults, with an additional 2.5 million patients.

  This patent application relates to the administration of nicotine antagonists, in particular mecamylamine (3-methylamino-2,2,3-trimethylnorcamphane). Mecamylamine is well known as an antagonist of nicotine and blocks ganglia stimulated by nicotine. Mecamylamine was first introduced as an antihypertensive drug, blocking the transmission of sympathetic ganglia, thereby causing vasodilation and lowering blood pressure (Non-patent Document 35). In general, ganglion blocking also results in relaxation of the bladder and gastrointestinal tract, sexual dysfunction, ciliary palsy, xerostomia, reduced sweating and orthostatic hypotension. Although the clinical use of mecamylamine as a ganglion agonist has been replaced by a more effective antihypertensive drug, scientists' interest in mecamylamine continues because mecamylamine has the ability to block nicotinic binding sites in the brain. (See, for example, Non-Patent Documents 36 and 37). These nicotine binding sites, known as nicotinic acetylcholine receptors (nAChr), are usually activated in the brain by acetylcholine, a prominent neurotransmitter.

  Nicotine obtained from tobacco is one of the most widely used drugs in various forms for many years (Non-patent Document 38). Nicotine functions as a regulator of nAChr (Non-patent Document 39). Through these receptors, nicotine activates presynaptic release of several neurotransmitters including acetylcholine, norepinephrine, cetronin and dopamine (Non-patent Document 40). A compound capable of acting on nAChr to modulate monoaminergic central nerve transmission can be an effective therapeutic agent for the treatment of neuropsychiatric diseases (Non-patent Documents 41 to 44).

  Unlike some ganglion inhibitors (drugs that do not easily reach the central nervous system (CNS)), mecamylamine has been reported to exert a central nervous effect in humans, for example nicotine Inhibits CNS action (Non-patent document 45), changes cognitive action (Non-patent document 46), changes electroencephalogram (Non-patent document 47), changes cortical blood flow (Non-patent document 48) Etc.

  Although most animal experiments use mecamylamine at 0.5 mg / kg or higher, Driscoll is a low dose (<0.3 mg / kg, not 0.5 mg / kg) in rats with high avoidance behavior. We found that mecamylamine showed an increase in the number of successful avoidance behaviors similar to 0.1 mg / kg nicotine (but less than 0.2 mg / kg nicotine) . Based on this experiment, Driscoll concludes that "mecamylamine may exert unpredictable effects on rats at doses used to inhibit nicotine in behavioral studies." (Non-patent document 49).

  In a recent study on the nicotine receptor (nicotine binding site) and its ion channel (mecamylamine binding site), Banerjee et al. Show that mecamylamine and several nicotine analogs have a strong affinity for the mecamylamine binding site. ) (Non-patent Document 50). Studies have also been conducted on alkaloids acting on nicotine receptor channels (Non-patent Document 51).

  Many neuropsychiatric disorders involve abnormal or involuntary movements, including obsessive-compulsive disorder (OCD), TS, ADHD, half-body muscle abnormalities, and Huntington's chorea, but such movements are limited to these Do not mean. These diseases are thought to be caused by an imbalance of neurochemicals in the basal ganglia of the brain. In humans, acetylcholine regulates motor behavior by activating nAChr in the basal ganglia. The action of nAChr in the basal ganglia has been well elucidated (Non-patent Document 52). Nicotinic stimulation activates the activity of dopamine (DA) -producing cells in the basal ganglia (Non-Patent Documents 53 and 54), but mecamylamine inhibits nAChr and releases DA from basal ganglion structures. (Non-patent document 55).

  U.S. Patent No. 6,057,037 to Rose and Levin discloses reducing the amount of nicotine and other drugs used by agonist-antagonist combinations. In combination with nicotine, the nicotinic antagonist mecamylamine is used to treat tobacco dependence. Rose and Levin suggest that the patch contain both nicotine and mecamylamine. Rose and Levin say that such agonist-antagonist combinations are other psychopathological disorders and neurological dysfunctions (eg manic depression, schizophrenia, hypertension, etc. due to sympathetic autonomic disorders) It also suggests that it can be used when containing.

  It is beneficial for patients to have excellent symptom control and few side effects. In particular, it is preferred to take a single agent, such as a patient in at least some of the reports disclosed herein. The inventors' clinical experience in human patients using mecamylamine for various diagnoses suggests various uses. The present invention discloses an improved method of symptom control by using a nicotine antagonist (mecamylamine) alone or in combination with a neuroleptic agent for the treatment of various nicotine responsive neuropsychiatric disorders.

U.S. Pat.No. 5,774,052

Tourette Syndrome Classification Study Group, Arch Neurol 50: 1013-16 Robertson, MM, Br J Psychiatry, 154: 147-169, 1989 Pauls, DL et al., Psychopharm Bull, 22: 730-733, 1986 Comings, DE, Himes, JA, Comings, BG, J Clin Psychiatry, 51: 463-469, 1990 Riddle, MA et al., “Willey Series: Child and Adolescent Mental Health”, Cohen, DJ, Bruun, RD, Leckman ), JF, John Wiley & Sons, New York, pp.151-162, 1988 Stelf, ME, Bornstein, RA, Hammond, L, “A Survey of Patients with Tourette Syndrome and Their Families: A Survey of Tourette Syndrome Association in 1987 ) ",, Cincinnati, Ohio Tourette Syndrome Association (1988), 1988), Harris, D, Silver AA, Learning Disabilities, 6 (1): 1-7, 1995 Silver, AA, Hagin, RA, "Disorders of Learning Childhood", Noshpitz, New York, Wiley, pp.469-508, 1990 Singer, HS, Ann Neurol, 12: 361-366, 1982 Erenberg, G, Cruze, RP, Rothner, AD, Ann Neurol, 22: 383-385, 1987 Shapiro, AK, Shapiro, E, “Wiley Series in Child and Adolescent Mental Health” Cohen, DJ, Brun , RD, Leckman, JF, John Wiley & Sons, New York, pp.267-280, 1988 Shapiro, ES et al., Arch Gen Psychiatry, 46: 722-730, 1989 Singer, HS, Gammon, K, Quaskey, S, Pediat Neuroscience, 12: 71-74, 1985-1986 Stamenkovic et al., Lancet 344: 1577-78, 1994 Bruun, RD, J Am Acad Child Psychiatry, 23: 126-133, 1984; Cohen, DJ et al., Arch Gen Psychiatry, 37: 1350-1357, 1980 Gonce, M, Berbeau, A, Can J Neurol Sci, 4: 279-283, 1977 Davidson, PW et al., Appl Res Ment Petardation 4: 1-4, 1983 Riddle, MA et al., J Am Acad Cild Adol Psychiatry 29: 45-48, 1990 Erenberg, G, Cruze, RP, Rothner, AD, Ann Neurol, 22: 383-385, 1987 Shapiro, AK, Shapiro, E, “Tourette's syndrome and Tic Disorders: Clinical Understanding and Treatment” Wiley Series: Childhood and Adolescent Mental Health "Cohen, DJ, Bruun, RD, Leckman, JF, John, NY John Wiley & Sons, pp.267-298, 1988 Erenberg, G, Cruze, RP, Rothner, AD, Ann Neurol, 22: 383-385, 1987 Montgomery, SP, Moss, DE, Manderscheid, PZ, "Mariluana 84", Harvey, DJ, Paton, WDM, IRL Press (IRL Press) ) (Oxford, UK), pp. 295-302, 1985 Moss, DE et al., Life Sci 44: 1421-1525, 1989 Sanberg, PR et al., Biomedicine and Pharmacotherapy 43: 19-23, 1989 Emerich, DF, Norman, AB, Sanberg, PR, Psychopharmacol Bull 27 (3): 385-390, 1990 Emerich, DF et al., Pharmacol Biochem Behav 38: 875-880, 1991 Sanberg, PR et al., Biomedicine and Pharmacotherapy 43: 19-23, 1989 McConville, BJ et al., Am J Psychiatry 148: 793-794, 1991 McConville, BJ et al., Biological Psychiatry, 31: 832-840, 1992 Silver, AA et al., “The Effects of Nicotine on Biological Systems II”, PBS Clarke, M. Quik and K. Thurau, “ Advances in Pharmacological Sciences ", Birkhauser Publishers, pp. 293-299, 1995 Silver, AA et al., J Amer Acad Child & Adolescent Psychiatry 35 (12): 1631-1636, 1996 Shytle, RD et al., Drug Development Research, 38 (3/4): 290-298, 1996 From Taylor, P, "Pharmacological Basis of Therapeutics", Goodman, LS, Gilman, A, McMillan Publishing, New York Martin, BR, Onaivi, ES, Martin, TJ, Biochemical Pharmacology 38: 3391-3397, 1989 Banerjee, S et al., Biochemical Pharmacology 40 (9): 2105-2110, 1990 Wilbwet, J, J Ethnopharmacol 32 (1-3): 179-186, 1991 Changeux, JP, Sci Amer (November), pp. 58-62, 1993 Balfour, DJK, Pharmacological therapeutics 16: 269-282, 1982 Jarvick, ME, Br J Addict 86: 571-575, 1991; Newhouse, PA, Hughes, JR, Br J Addict 86: 521-526, 1991; Hughes, J, Clarke, PBS, “The effects of nicotine on biological systems II / Summary S40”, 1994 Decker, MW et al., Life Sci 56: 545-570, 1995 Martin, BR, Onaivi, ES, Martin, TJ, Biochemical Pharmacology 38: 3391-3397, 1989 Newhouse, PA et al. Neuropsychopharmacology 10: 93-107, 1994 Pickworth, WB, Herning, RI, Henningfield, JE, Pharmacology Biochemistry & Behavior 30: 149-153, 1988 Gitalman, DR, Prohovnik, I, Neurobiology of Aging 13: 313-318, 1992 Driscoll, P, Psyciopharmacologia (Berl) 46: 119-21, 1976 Banerjee, S et al., Biochem Pharmacol 40 (9): 2105-10, 1990 Daly, JW, “Alkaloids as Agonists, Antagonists and Noncompetitive Blockers of Nicotinic Receptor Channels” (“Nicotinic acetylcholine receptors as drug targets” (Nicotinic Acetylcholine Receptors as Pharmaceutical Targets) Abstract, July 24-25, 1997, Washington, DC Clark, PBS, Part, A, Brain Res 348: 355-358, 1985 Clerk, PBS, J Pharmacol Exper Therapeutics 246: 701-708, 198847; Grenhoff, J, Aston-Johns, G, Svennson, TH, Acta Physiol Acand 128: 351 -358, 1986 Imperato, A, Muras, A, Di Chiara, G, Eur J Pharmacol 132: 337-338, 1986 Ahtee, L, Kaakkola, S, Br J Pharmacol 62: 213-218, 1978

  The object of the present invention is to provide a new treatment for patients with nicotine responsive neuropsychiatric disorders.

  It is a further object of the present invention to provide a treatment with fewer side effects, resulting in improved patient compliance, improved quality of life and improved social function.

  Disclosed herein is a method of treating a patient having a nicotine responsive neuropsychiatric disorder comprising administering an effective amount of a nicotine antagonist. Preferably, the nicotine antagonist is mecamylamine, a stereoisomer, or a mecamylamine analog. An effective amount of mecamylamine is an amount that improves a patient's signs and symptoms. In tic disorders, the amount that reduces the frequency and / or severity of tics in each patient. In addition, there may be an additional step of administering an effective amount of a neuroleptic agent to the patient. Examples of neuroleptic agents include haloperidol, pimozide, fluphenazine and risperidone.

  Examples of nicotine responsive diseases include movement disorders including Tourette's syndrome, essential tremor, half-body muscle abnormalities, late movement disorders and Huntington's chorea (HD). Other nicotine responsive mental disorders include schizophrenia, mania, attention deficit hyperactivity disorder, manic depression, rage outbreak and obsessive compulsive disorder.

Chemical structural formula of mecamylamine and several other nicotinic antagonists.

  The inventors have previously provided nicotine in addition to or subsequent to neuroleptic treatment with haloperidol to provide rapid and significant relief for tic disorders and other TS syndromes that could not be controlled with neuroleptic drugs alone. It shows that it brings. Using neuroleptic-inducing catalepsy as a model to understand the therapeutic effects of neuroleptics and nicotine in TS patients, uninhibited striatal cholinergic interneurons (which are striatal mantle GABA It was thought that nicotine enhances the activity of D2 antagonists in catalepsy by activating innervated process neurons. Thus, pallidal inhibition also occurs (Emerich, DF et al., Pharmacol Biochem Behav 38: 875-880, 1991). However, because nicotine has complex neuropharmacological effects, it is difficult to explain the exact mechanism by which nicotine interacts with neuroleptic drugs to reduce TS symptoms. One hypothesis is that nicotine penetrating from the skin exerts its therapeutic effect by continuously inactivating the nicotine receptor (Shytle, RD et al., Drud Development Research 38 (3 / 4): 290-298, 1996). Neuropharmacological effects consistent with this hypothesis have been observed in vitro (Lukas, RJ, Drug Dev Res 38: 136-48, 1996).

  In several TS patients who do not respond to conventional treatment, the inventors have discovered that the nicotine receptor antagonist mecamylamine is suitable for treating hypertension and reducing TS symptoms. After treatment with mecamylamine alone or in combination with neuroleptics, it was unexpected that TS syndrome improved, which is generally considered to be the effect of mecamylamine relative to nicotine. That is, if nicotine relieves tic disorder, mecamylamine is considered to make tic disorder more severe. Thus, it is a surprising discovery that significant relief was observed in patients with mecamylamine treatment. The inventors thought that in addition to mecamylamine, other nicotine receptor antagonists described in detail below can also be used. Furthermore, considering the effects on concurrent medical conditions, nicotine receptor antagonists are not only TS, but also other neuropsychiatric disorders (eg attention deficit hyperactivity disorder (ADHD), obsessive compulsive disorder (OCD), essential vibration) It was also considered effective for epilepsy (ET), late movement disorder (TD), mania (D) and Huntington's chorea (HD). Nicotine antagonists are expected to be effective in other nicotine responsive diseases such as schizophrenia, mania, manic depression, rage and panic.

  Abdominal muscle tone is also nicotine responsive and is a localized movement disorder involving arms and legs on one side of the body. In general, it progresses as an adult, and the symptoms persist and rarely spread to the body without any abnormalities. This is one of the symptoms including convulsive torticollis (intermittent convulsion that turns the head up and down). Benzodiazepines, baclofen, carbamazepine, reserpine and eldopa are used to improve symptoms in general and partial muscle tone involving a wider part of the body. In severe focal muscle tone, diluted botulinum toxin may be injected into the problem muscle or the nerve may be surgically removed. One-sided muscle tone abnormalities can be expected to react to mecamylamine.

The definition “nicotine antagonist” is a broad and expanding category, and mecamylamine is just one example. A list covering all such compounds cannot be published due to space limitations. The following description is not intended to be exhaustive of the compounds encompassed by this term but teaches how to confirm. Recently, a study on interesting nicotine antagonists and related compounds has been reported by Daly, JW (Id.), Which is incorporated by reference. Clark and Reuben disclose dihydro-β-erythroidine, methyllicaconitine, chlorisondamine and trimetaphane (Br. J. Pharmacol. 117: 595-601, 1996). Normecamylamine, N- (1,2,2) trimethyl-1-bicyclo [2,2,1] -heptibenzenamine, dimethylaminoisocamphane, exo-aminonorbornane, 2,2,6,6-tetramethyl Piperidine, 2,2,6,6-tetramethyl-4-aminopiperidine and penpidine have been identified as active nicotine antagonists (Banerjee, Biochemical Pharmacology 40: 2105-2110, 1990). This document and the test methods described therein are incorporated herein by reference. Additional examples of nicotine antagonists include erysodine (Decker, European Journal of Pharmacology 280: 79-89, 1995), phenyltropanecarboxylic acid methyl esters (Lerner-Marmarosh et al., Life Sciences 56 ( 3): PL67-70, 1995), allyl penpidine analogues (Wang et al., Life Sciences 60 (15): 1271-1277, 1997), Ibogaine (Daly, Biochemical Pharmacology 40 (9): 2105-2110, 1990).

  In addition, activity studies have been conducted on various stereoisomers and substituted analogs of mecamylamine (Stone et al., J Med Pharm Chem 5 (4): 665-90, 1962: referenced herein). As well) When tested for nicotinic convulsions and mydriasis in rats, activity was usually lost when the methyl group was replaced with a larger substituent. Any methyl or dimethyl group on the amino group was more active than the other substituents. The d form was active; however, the dl racemate was slightly more active. Therefore, in this use of mecamylamine, it is considered that the l-form has a remarkable activity. Stone et al. Found that the exo form (where the methylamino group is on the same plane as the methylene bridge) is in the endo form (the methylamino group is below the methylene bridge, in the cage formed by the bridge). It has always been more powerful than existing). Furthermore, the partial structure 2,2-dimethyl-3-methylaminobutane was also active. Some differences in activity were observed between various models of d-form and other analogs, suggesting the possibility of different activities and effects in neuropsychiatric disorders.

  For other compounds that are expected to be theoretically active in such applications, see US Pat. No. 4,837,218 (Alkylated Bicycloalkaneamines for Neurotoxic Injury), US Patent US Pat. No. 2,894,987 (N-allyl-2-aminoisocamphan), US Pat. No. 3,148,118 (Analeptically Active Agents), US Pat. No. 3,164,601 (N-substituted aminos having excitatory activity) Norkanphan derivatives (Analeptically Active N-Sucstituted Aminonorcamphane Derivatives)). These patents are incorporated for reference.

  “Benefit effect” refers to a marked improvement in clinically observed signs and symptoms over standards. For example, beneficial effects in movement disorders include a decrease in the frequency and severity of tick disease, but not only that, anxiety, aggressive rage and often preceded or overlapped with the severity of abnormal behavior This includes improvements that are not directly visible, such as a reduction in the signs of urgency. The therapeutic effect can be quantified by clinical observation and videotape evaluation. Beneficial effects in obsessive-compulsive disorder include a reduction in compulsive behavior, which can be confirmed by patient reports. Suemaru et al. (Supra) suggest that nicotine-induced rat tail tremor can be used to screen for compounds that treat tremor. Repeated administration of nicotine can induce motor hyperactivity and tail tremor in rats, which can be blocked with mecamylamine (0.1-1 mg / day, ip), but hexamethonium Then it cannot be blocked because it cannot easily reach the brain. Centrally active clonidine (adrenergic agonists) and prazosin (adrenergic antagonists) significantly reduced tail tremor rather than hyperactivity. However, the centrally active haloperidol and chlorpromazine (dopamine antagonists) significantly reduced hypermotility over tail tremor (Suemaru, K., Oishi, R., Gomita). ), Y, Arch Pharm 350: 153-57, 1994).

  The Yale Global Tic Severity Scale (YGTTS) is the most widely used clinical assessment rating and is used to assess tic disorders. This provides an objective measure of the frequency and severity of tic disorders based on clinical observations. This scale includes a survey of tic disorders that is completed based on the patient's own memory of tics that occurred in the previous week. Using this survey table as a guide, physicians rank severity for both motor and phonic tics with respect to five independent numbers (number, frequency, intensity, complexity and interference). In addition, there is an extensive damage assessment in the previous week that describes the impact of the disease on the patient's social role, self-esteem, etc.

  An objective way to assess tic disorder is to record the patient on video. Watch a video tape of at least 5 minutes and record the frequency and severity for both motor tics and phonic tics. Video recordings are for drug trials (Leckman, JF et al., Arch Gen Psychiatry, 48: 324-328, 1991; Shapiro, ES et al., Arch Gen Psychiatry, 46: 722-730, 1989; McConville ), BJ, Fogelson, HM, Norman, AB, Klykylo, WM, Manderscheid, MA, Parker, KW, Sanberg, PR, Am J Psychiatry, 148: 793-794, 1991; Silver, AA, Shytle, RD, Philipp, KK, Sanberg, PR, “The Effects of Nicotine in Biological Systems (The Effects of Nicotine on Biological Systems II ", PBS Clarke, edited by M. Quik and K. Thurau," Advances in Pharmacological Sciences ", Birkhauser Publishers Pp. 293-299, 1995); Reveley, MA et al., Journal of Psychopharmacology Suppliment, A30, 117, 1994) and important for clinical evaluation systems for challenge studies (Chappel, PB et al., Adv Neurol 58: 253-262, 1992) Has proven to be a good help. In a recent report, Chappel and co-workers confirmed video and audiotic tics by videotape and correlate well with the established clinical evaluation scale. (Chappel, PB et al., J Am Acad Child Adolesc Psychiatry, 33: 386-393, 1994).

  As used herein, a “nerve relaxant” refers to an agent that affects thoughts, emotions, and neurological conditions, particularly movement and posture (as seen in the case of TS). Almost all neuroleptic drugs have a powerful effect on the extrapyramidal path that causes late movement disorders (see above). Examples of neuroleptic drugs include haloperidol (trade name Haldol, McNeil Pharmaceutical (Raritan, NJ)), pimozide (trade name Orap, Teva Pharmaceuticals (Teva). Pharmaceuticals) (Carpsville, PA)), fluphenazine and risperidone (trade names Risperdal, Janssen Pharmaceutical (Janssen, NJ)) and the like.

  “Effective dose” refers to the amount of nicotine antagonist necessary to obtain an effect. The required dosage will vary depending on the compound selected, the age and weight of the patient, the severity of the disease, the route of administration, etc., but is readily determined by routine experimentation as described in the clinical examples below. can do. In general, however, an effective dosage is about 0.001 mg / kg to about 6 mg / kg per day, preferably about 0.002 mg / kg to about 3 mg / kg per day, more preferably about 0.005 mg per day. / kg to about 2 mg / kg, and most preferably about 0.01 mg / kg to about 1.5 mg / kg per day. The starting dose for adults with drug-resistant TS is about 2.5 mg / day, and the dose is adjusted according to symptom recurrence (see cases below). For younger children with moderate ADHD, it is preferable to start at 1 mg / day or less. The effective dose of a neuroleptic is the smallest amount that will relieve symptoms when combined with a nicotine antagonist. Our clinical experience suggests that in some patients, it may be possible to obtain the maximum therapeutic effect without using neuroleptics.

  “Pharmaceutically acceptable” refers to the absence of unacceptable toxicity to a compound such as a salt or excipient. Pharmaceutically acceptable salts include inorganic anions such as chlorine, bromine, iodine, sulfite, sulfate, nitrite, nitrate, phosphate, and acetate, malonate, pyruvate, And organic anions such as propionate, cinnamate, tosylate and citrate. Pharmaceutically acceptable excipients are described in detail by Martin, EW in “Remington7s Pharmaceutical Sciences” (Mac Pub.). .

  A pharmaceutical composition containing a nicotine antagonist may include one or more pharmaceutical carriers. The term “pharmaceutically acceptable carrier” refers to any generally acceptable excipient that is relatively inert, non-toxic and non-irritating. When the carrier is a diluent, it can be a solid, semi-solid, or liquid material that acts as a vehicle, excipient or medium for the active ingredient. Pharmaceutical unit dosage forms are prepared for any of the several routes of administration, including oral and parenteral (especially by intramuscular and intravenous injection, or subcutaneous implantation or transdermal administration). can do. Representative of such forms include tablets, soft and hard gelatin capsules, powders, troches, chewing gums, emulsions, suspensions, syrups, solutions, sterile injectable solutions and sterile filled powders. . A composition containing a nicotine antagonist can be formulated by methods known in the art to release any or all compounds rapidly, sustained or delayed after administration.

  The nicotine antagonist formulations of the present invention are suitable for oral administration and can be formulated into tablets or capsules using preferred carriers. Solid pharmaceutical excipients (magnesium stearate, calcium carbonate, silica, starch, sucrose, dextrose, polyethylene glycol (PEG), talc, etc.) and other conventional pharmaceutical adjuvants (fillers, lubricants) , Wetting agents, preservatives, anti-degradation agents, perfumes, etc.) and binders (gelatin, gum arabic, cellulose, methylcellulose, etc.), used as described above, or tableted, encapsulated, or as described above Mixtures for preparing other suitable forms can be obtained. See “Remington 7s Pharmaceutical Sciences” (Mac Pub.) For a general description of formulation.

The administration mode is preferably oral administration, but may be transdermal application, nasal spray, bronchial inhalation, suppository, parenteral injection (for example, intramuscular or intravenous injection) and the like. Carriers for parenteral administration include dextrose, mannitol, mannose, sorbitol aqueous solution, physiological saline, pure water, ethanol, glycerol, propylene glycol, peanut oil, sesame oil, polyoxyethylene-polyoxypropylene block polymer, and the like. However, it is not limited to these. Appropriate preservatives, stabilizers, antioxidants, antimicrobial agents and buffers (eg, BHA, BHT, citric acid, ascorbic acid, tetracycline, etc.) can additionally be included. Alternatively, a sustained release system suitable for implantation or application to the skin can be provided by incorporating or encapsulating the nicotine antagonist formulation within a suitable polymer matrix or membrane. Other systems include devices such as endogenous catheters and the brand name Alzet minipump.

  As described above, the present invention has been described directly, but examples relating to the effects of the beneficial method will be described below. The following examples are merely illustrative and are not intended to limit the scope of the method.

Clinical Example Patient 1 is a tall, 15 year old boy diagnosed with TS weighing 78.6 kg. This patient is the patient of our clinic, and for the purpose of effectively controlling severe TS symptoms, haloperidol 2 mg / day and twice a week transdermal nicotine patch (14 mg / 24 hours) for about one year. ) Was prescribed. However, the tic disorder (which was well controlled until then) recurred approximately two months before the planned follow-up. At that time, the dose of haloperidol was increased to 3 mg / day, and the frequency of applying nicotine patches was increased every other day, with some improvement. However, the side effects of nicotine patches, especially nausea, have afflicted patients and led to rejection of the patches. In addition, the increased risk of nicotine addiction from daily use has discouraged patients from continuing to use the patch.

  The patient discontinued the nicotine patch two weeks before coming to the clinic. Blinks, raised eyebrows, distorted face, head reflexes, abdominal tics, and leg / foot movements were observed. The patient had a YGTSS score of 17/30, a total of 245 five-minute tics, and an overall severity rating of 3 (moderate) on a 7-scale scale.

  At around 11:30 am, mecamylamine (5 mg) was orally administered. About 2 hours later, the patient reported that the urge for tic disorder had decreased. The YGTSS score was 6/20. Although tics still remain, the frequency of tics has decreased by 25%. Overall tic severity was reduced to 50%. By 6 pm, the patient's mother reported that the patient was feeling well, no tics were visible, and there were no side effects. However, the next morning the tic disorder began to recur. One month later, ticosis was controlled by taking mecamylamine 5 mg / day at breakfast, and the patient reported that the tension had eased and became cautious. Up until 30 days ago, the boy who was shy and silent began to speak well with extroversion.

  Clinical experience in the treatment of this first patient suggested that the combination of haloperidol and mecamylamine can suppress motile tic disorders. The effect of a single oral administration of mecamylamine appeared after 2-3 hours and lasted for about 8-12 hours. Mecamylamine daily dose continued for 211 days with no side effects.

  Patient 2 was a 16-year-old boy in the third grade of junior high school. Although the overall cognitive function was excellent, the visual motor function was severely defective. This patient was at the age of 10 because of attention deficit disorder and learning difficulties because of methylphenidate and dexedrine (dextroamphetamine sulfate, SmithKline Beecham (Philadelphia, PA)) Administration began and motility and phonetic tics developed within 6 months. The patient's parents reported that the patient's tic disorder was suppressed by using 0.1 mg clonidine three times a day. However, for the last two years no medications have been prescribed for motor and voice tics. At the end of the second year of junior high school, I failed in mathematics, and in other subjects I was given a C or D rating, and the difficulty of visual motor function was noticeable. Writing was slow and struggling. I refused to write, became frustrated in writing, and felt fate to fail. When the patient visited the inventors' clinic, tic disorders were apparent: blinking, mouth distortion, large body ticks, quick movements and reflexes of the shoulders, head tics, and sniffing. The patient complained (being embarrassed) that "the mind is active". During the summer, the patient tried to learn mathematics and was able to take the exam again and entered high school in the fall. However, despite the fact that the process is known in the head, it was difficult for the patient to write down the process (such as required in the test) required to answer the mathematical problem. The patient could not stand, was frustrated and was about to throw.

  Mecamylamine was prescribed and instructed to take it after dinner. The patient's mother (nurse) reported that the patient began studying mathematics 2 hours after taking 5 mg of mecamylamine. At this time, the patient was patient and felt “clear”, unfastened and tackled the math problem for 3 hours without distraction. The patient's tic disorder was reduced in both intensity and frequency. The next morning, the patient felt uncomfortable and the tic disorder recurred, although not as bad as before. There were blinks and large reflexive body movements. The patient was prescribed 5 mg mecamylamine at breakfast and 2.5 mg after dinner. Twelve days later, the patient reported that she was able to concentrate on her studies rather than being “uplifted” as before. Although tics occasionally appear, they have been attenuated. Blood pressure did not change 114/80. In this patient, neuroleptics were not administered in combination with mecamylamine, suggesting that mecamylamine alone can suppress TS. After 8 weeks of treatment, the patient's mother reported that the patient was doing well, wanted to continue treatment, and entered high school. The patient continued to use mecamylamine for 208 days with no side effects.

  Patient 3 was a 35-year-old woman who had had TS from severe motor dysfunction, phonic tics and obsessive compulsive disorder since the age of 6. The patient was a mother of three children, and the older 12-year-old girl also had TS. Over the years, various drugs have been tried to control mania and mood swings, including Zoloft (sertraline hydrochloride, Pfizer Roerig Division, New York). In July 1996, we tried a transdermal nicotine patch (7 mg) at our clinic, and the tic disorder was attenuated within 3 hours. However, the use of the patch was discontinued because the knee, ankle and wrist joints began to ache and swollen within the next 24 hours. A trial dose of haloperidol (0.5 mg) was administered. Within 12 hours, there was a rapid rise in body temperature that required discontinuation of haloperidol. In a follow-up diagnosis after one year at our clinic, the patient is tense and unpleasant, with multiple severe tic disorders (almost continuous blinking, distortion, nasal cramps, sniffing) ) As well as the obsession that everything in the house must be “contained”.

  I took 5mg mecamylamine at 2pm. At 5 pm, tic disease still remained, but it was clearly reduced and the intensity dropped significantly (50%). The patient continued 5 mg mecamylamine for 4 days and reported that tic disease remained but weakened. The patient reported feeling relaxed with less anxiety. In addition, while taking mecamylamine, he reported a decrease in the sense of urgency for rage outbreaks seen in stressful situations. Mecamylamine was administered once daily for 30 days, but no significant changes in blood pressure or heart rate were observed. The patient complained of constipation during the menstrual period but reported no other side effects. When the mecamylamine prescription was completed, the patient requested continuation of mecamylamine. In the case of this patient, as in the case of Patient 2, a neuroleptic agent was unnecessary. The patient said that he took mecamylamine for 195 days and was glad that he was less likely to get irritated at the time of diagnosis, but he said he stopped taking mecamylamine because he was unable to throw away his “uplifted” feeling.

  Patient 4 is a 43-year-old male salesman with a TS history since the age of 14. The patient had used haloperidol (0.5 mg twice daily) and a 14 mg transdermal nicotine patch twice a week, but had no complete control of motility and phonic tics. Rather than increasing the dose of haloperidol or increasing the frequency of nicotine patches, nicotine patches were discontinued and mecamylamine (5 mg / day) was prescribed. Initially, YGTSS was 27/30, and from a 5 minute videotape, the total number of ticks was 207, and the overall severity on a 7-step scale was 4 (very significant). About 90 minutes after the first dose of mecamylamine, the patient reported feeling relaxed. YGTSS was 20/20 and severity was 2.5 (somewhat marked). After 6 hours, the patient reported that she continued to feel relaxed, with no facial distortion and head cramps. I was blinking, but it was alleviating. However, by the next morning, tic disease began to recur. When 5 mg mecamylamine was taken at breakfast, tic alleviation was regained within 1-2 hours. The tic disorder began to recur after about 8 hours. As an additional dose, 2.5 mg mecamylamine was prescribed before dinner. This dose reduced evening motility and phonetic tics. As maintenance doses, mecamylamine was prescribed 5 mg at breakfast and 2.5 mg before dinner. Haloperidol (0.5 mg, twice daily) continued. Nicotine interrupted. Motility and phonetic tics were controlled by the combination use of small doses of mecamylamine and haloperidol.

  Recently, Patient 4 reported that his physician was unable to determine the cause of chronic fatigue that had begun before the start of mecamylamine treatment. There was no change in blood pressure. However, he discontinued the patient's mecamylamine and resumed the nicotine patch.

  Patient 5 was an 18-year-old man and his first visit was at the age of 15. Since the age of 10, he has been treating TS syndrome with 16 mg / day of pimozide (Orap, Teva Pharmaceuticals, Inc., Calpsville, Pa.). The patient had a strong family history of tic disorder. The patient's mother, maternal grandmother, maternal uncle, and cousin all showed Tourette syndrome. At the first visit, the patient took 12 mg of pimozide with the brand name Prozac (fluoxetine hydrochloride, Eli Lilly (Indianapolis, Ind.)). Motility tics were slight, but with a severe Parkinson-like look, they were blocked, and fine hand shaking worsened due to tension. When pimozide was reduced to 4 mg / day and Prozac was discontinued, gonorrhea and Parkinson-like symptoms, except for persistent hand shaking, alleviated. During the treatment period under the inventors, abnormal EEG with moderate background division and sensitive movements on the left temporal region were observed. Patients were treated with carbabazepine, haloperidol, and the brand name Cogentin (Benztropine mesylate, Merck (West Point, Pa.)) With significant reductions in motility and phonic tics . However, tremors persist and obsessive-compulsive disorder has prevailed. The patient said he was unable to concentrate on his work because his heart was wandering elsewhere. Attempting a nicotine patch resulted in nausea, headache, and nonsubmission. Two months after visiting the clinic, he took a test dose of 2.5 mg mecamylamine. Within two hours, the patient said, “I feel calm” and said I feel like I can get back to studying at a community college. In addition, the hand shaking that had been complaining before mecamylamine administration almost disappeared.

  Patient 6 was a 23-year-old male who had had severe Tourette syndrome since his second year of elementary school. Over the years, this patient has been treated with a number of neuroleptic drugs, as well as clonidine and clonazepam (brand names Klonopin, Roche Laboratories (Nutley, NJ)). At the first visit, the patient had been taking 12 mg / day of pimozide for at least 2 years and worked as a counselor in a camp for children with emotional disorders. The patient failed twice the exam for the course to become an emergency care worker. The patient's Tourette syndrome was the most severe of those seen at the inventors' clinics. The patient was constantly moving, talked reluctantly, had a tic-like distortion in the face, shrugged shoulders, and copropraxia (the patient's fingertip was pointing to the groin), but the most common symptoms Was a proverb. All words were originally emphasized, suppressed, separated and large with interjections having sexual meaning. The patient was trying to hide with a smile and cheer. However, the patient felt afraid and depressed, and the fingers were clearly shaking. Neuropsychological tests revealed severe visual motor impairment. The test dose of 7 mg transdermal nicotine patch slightly reduced the intensity of tic disorders and proverbs. However, within 4 hours the patient complained of nausea and dizziness. While increasing the time for applying the nicotine patch, we tried using it once a day for a week. However, side effects persisted and nicotine was discontinued.

  Two weeks after nicotine was excreted from the body, 2.5 mg of mecamylamine was prescribed once a day. After 7 days, the patient reported that about 70% of the proverbs had disappeared. In the follow-up diagnosis at this time, not only proverbs were significantly reduced, but the remaining ones were whispers. The restless movement stopped so that the facial distortion disappeared. Only a slight shaking of the hand remained.

  Patient 7 is a 16-year-old female high school student, and his first visit was in July 1997. He has a long history of Tourette's syndrome. He has been taking Klonopin 1 mg three times a day for obsessive-compulsive disorder and gonorrhea. Adding 25 mg of sertraline twice daily and a transdermal nicotine patch showed a marked improvement in tics and emotions. However, the nicotine patch was immediately discontinued due to side effects of the nicotine patch, including headache and nausea. In mid-August 1997, 2.5 mg mecamylamine was prescribed, sertraline was gradually discontinued, and chronopin was reduced to 1 mg / day. Within a few days, the patient reported that the tic disorder was “significantly reduced” and the irritation subsided and he felt better. However, in early December 1997, the patient's mother reported that “aggression and loss of confidence” began to reappear, and the sniffing voice tics returned. Mecamylamine was increased to 3.75 mg / day to reduce mania, moodiness and irritability, slightly improved tics (+4 to +5 on a 10-step scale), and improved attitudes towards school and friends. There were no complaints regarding the side effects of mecamylamine.

  Patient 8 is a small, thin 9-year-old boy who was diagnosed with ADHD at the age of 5 and took methylphenidate (20 mg twice a day) about 6 months before visiting our clinic. It was. Attention increased by methylphenidate, and a strong behavioral sensation was weak, but motor tic disorder developed within 4 months of the start of use. Therefore, the use of methylphenidate was discontinued and 7 mg transdermal nicotine patch was found unacceptable due to nausea. Mecamylamine 2.5 mg produced minimal effects, but 3.75 mg / day suppressed overexercise and continued attention. The patient said he felt well and could no longer hear the “devil's voice”. On the overall improvement scale, the patient's mother rated 10 + 3. No side effects were reported for 210 days of use.

  Patient 9 was a boy who visited the inventors' clinic at 11 months. Because of the patient's resistance, the patient's mother left the patient with a paternal uncle who lives in another state. When revisiting the inventors' clinic at the age of 14, motility and phonetic illness were still severe, but the patient was seeking treatment. Symptoms were alleviated using risperidone (2 mg / day) and a transdermal nicotine patch (7 mg / day, about twice a week). However, the patient was still grumpy, frustrated and complaining. Mecamylamine 2.5mg / day was added. Within 3 weeks, the patient's mother reported that the patient had “improved like never before” since she added mecamylamine, calmed down, disappeared, and reduced the outbreak of rage. During the follow-up diagnosis period of 6 months after the start of taking mecamylamine, the patient's grandmother interrupted risperidone at her own will, and about 5 months after the start of treatment, mecamylamine was also at her own will. Was reported to have been suspended. Patients continue to use nicotine patches "usually more than once a week". The patient's grandmother reports that the patient's tic disorder is largely suppressed, but is complaining and occasionally furious.

  Patient 10 is a 37-year-old smoking man with alcoholism. He was in a manic state, presented with severe and unacceptable proverbs and anxious attacks, treated with antidepressants, benzodiazepines and haloperidol, with only minor improvement in symptoms. Although she was taking medication, she was not effective. On July 1, 1997, mecamylamine 2.5 mg / day was started. The patient reported that he was "relaxed, spoke well (had less proverbs), and began to speak fluently". However, the patient complained of “headache and heartburn”. Mecamylamine was re-administered on December 8, 1997. The initial dose of 2.5 mg suppressed the proverbs for about 1 hour, and the patient subsequently complained that “I became irritated and nervous”. Mecamylamine was interrupted.

  Patient 11 is a 14-year-old boy with Tourette syndrome, ADHD, OCD, severe visual and motor impairment, anxiety, and loss of confidence. The patient's thumb peel was associated with the patient feeling "incomplete" and physically different from classmates. Symptoms were controlled to some extent by haloperidol. The transdermal nicotine patch enhanced the therapeutic effect of haloperidol, but the patient eventually refused the patch because the patch was uncomfortable and nausea. On July 17, 1997, mecamylamine 2.5 mg / day was started. Within 3 hours of the first dose, the patient's movements decreased and calmed down. The severity of the patient's tic disorder was significantly reduced. There were no side effects and blood pressure was maintained at 110-114 / 70-76. Within one week of starting mecamylamine, the patient's mother reported a significant improvement in mood and behavior, reduced irritation, and a fun relationship with her parents. “The patient no longer beats his brother.” The ongoing doses of haloperidone and clonidine were reduced. Mecamylamine continued for 215 days. During this period, the patient “very improved” in mood, behavior and attitude to school. However, persistent cough did not recover. To stop the cough, mecamylamine was discontinued and sertraline was started. Troublesome coughs began to occur only at mealtime. We are considering returning to mecamylamine treatment.

  Patient 12 was a boy who started methylphenidate as a treatment for distraction and hyperactivity at age 9. I developed tic disorder in the month I started methylphenidate. The symptoms of Tourette syndrome, OCD and ADHD worsened. The patient was taking a combination of pimozide, haloperidol, Prozac, and Paxil, which provided some control over the tics, but increased mania and increased doze at school, so at 14.5 years Two months before visiting the inventor's clinic, he left home from school (second-year junior high school) and was studying at home. The patient gradually reduced the variety of medications prescribed to only 2 mg of haloperidol and added clonidine, but the symptoms remained almost unchanged. Symptoms were alleviated by using a transdermal nicotine patch (7 mg) twice a week. However, when nicotine was discontinued and mecamylamine 3.75 mg / day was added, there was a clear improvement in motility and phonic tics. Although the tic disorder remained slightly, it was significantly reduced and the intensity decreased. The patient felt relaxed. The patient is doing well at school and is participating in a high school exercise program. There is no longer immaturity in the Bender-Gestalt test. The patient's blood pressure was 114/80 in December 1997 and 100/70 on June 12, 1998. There were no complaints of side effects.

  Patient 13 is a 12-year-old boy who has been examined at the inventor's clinic since age 9. Motor and phonetic tics and compulsive behavior worsened after age 4 and worsened after age 7. Repeated EEG showed abnormal “grade 3 irregularity, independent centrality on both sides, and temporary spikes at the top of the head”. All symptoms were aggravated by Tegretol. Standard prescriptions have made it difficult to control patient motility and phonetic tics. Although nicotine helped relieve tic disorders, patients were associated with nicotine-sensitive and unacceptable side effects. Mecamylamine 2.5 mg / day was started on August 13, 1997. The patient reported that he was “calm and not complaining so much”. However, the improvement lasted only for 3-5 days, the tic disorder recurred, and the headache became severe. Increasing the dose of 5 mg / day did not reduce tic disorder but increased headache. Blood pressure was usually between 110/76 but decreased to 90/68. The heart rate was usually 70-76, but it became 68. Mecamylamine was interrupted.

  Patient 14 was a 9 year old boy. He had apparent dysgenesis, his physique was small, his head was triangular, and he was constantly moving and talking about his guns and weapons. The patient had severe motility and phonetic tics, proverbs, contact obsession, and apparent anxiety. The patient was prescribed a variety of drugs, including carbabazepine and methylphenidate, but only increased exercise. Haloperidol reduced patient activity, but the effect lasted only 3 weeks. The transdermal nicotine patch (7 mg) only caused nausea. Even with mecamylamine 1.25mg / day, the restlessness increased, tears were fragile and only frustrated. Mecamylamine was discontinued after 10 days.

  Summary of findings: As noted above, 12 out of 14 patients had improved tic disorder and mood after taking mecamylamine. All but one reported that their feelings were relaxed. The two women patients were upset by the medication. There was a significant change in blood pressure in one patient at the dose taken. Since high dose mecamylamine is used to treat hypertension, the dose should be low and well tolerated. These patients had multiple symptoms. In addition to TS, Patient 2 had ADHD and compulsion, but both improved with new treatments. Patients 3 and 7 also showed obsessive-compulsive behavior, but decreased with mecamylamine treatment. In addition, Patient 5 had hand shaking but decreased after mecamylamine administration. In this group of patients treated with mecamylamine, distraction, hyperactivity, tremors, obsessive-compulsive behavior, mania and mood swings, and Tourette syndrome motility and phonetic tics The symptoms were reduced.

The doses for these TS patients whose symptoms could not be controlled by conventional treatment are summarized in Table 1 below. The dose range was about 0.03 to 0.10 mg / kg. Table 2 was calculated using this range.

Other uses In recent reports, nicotine has been associated with schizophrenia (Adler, LE et al., Am J Psychiatry 150: 1856-1861, 1993), attention deficit hyperkinetic disease (ADHD) (Levin, ED). Et al., Psychopharmacology 123: 55-62, 1995) and mania (Salin-Pascual, RJ et al., Psychopharmacology 121 (4): 476-479, 1995) have been suggested. In general, the therapeutic action of nicotine in these “nicotine responsive” diseases is believed to be due to activation of nAChr (Decker, MW et al., Life Sci 56: 545-570, 1995). However, like many other drugs, nicotine clearly has complex neuropharmacological effects. Thus, many patients with such nicotine responsive diseases can be treated with nAChr blockers such as mecamylamine disclosed as examples herein, where nAChr blockers are nicotine responsive diseases. Alleviated some TS and ADHD symptoms.

  Schizophrenia is a psychiatric disorder that is presumed to exhibit an excessive dopamine state, and is often treated with neuroleptics, but is thought to be a nicotine responsive disease. For example, when schizophrenic patients were investigated, smoking rates ranged from 74% to 92%, compared to 35% -54% for all patients with psychosis and 30-35% in the general population. Cigarette smoking is thought to increase concentration and reduce anxiety by overstimulation and improve potential psychosis (Gopalaswamy, AK, Morgan, R, Br J Psychiatry 149: 523, 1986). In addition, nicotine may play some role in improving cognitive deficits associated with schizophrenia and neuroleptic treatment. Cigarette smoking has been found to normalize perceptual gland defects in patients with schizophrenia (Adler, LE et al., Am J Psychiatry 150: 1856-1861, 1993). Nicotine transdermally recovered some of the cognitive side effects of standard antipsychotic therapy and improved cognitive performance in common schizophrenic patients (Levin, ED et al., Psychopharmacology 123: 55-62, 1995). Assuming that nicotine administration really has the same effect as nAChr blocker administration, nAChr blockers such as mecamylamine and related compounds can also restore some of the cognitive side effects of antipsychotic treatment and It should be possible to improve cognitive performance in patients with schizophrenia. In addition, nicotine enhances the therapeutic effects of neuroleptics on TS (McConville, BJ et al., Biological Psychiatry 31: 832-840, 1992), and thus "neurology such as schizophrenia and Huntington's chorea. The use of mecamylamine as an adjunct to "relaxing drug responsive" disease can reduce neuroleptic dosage, thereby reducing the side effects of neuroleptic drugs without diminishing the therapeutic effect. it can.

  The above description and examples are illustrative only and are not intended to limit the scope of the present invention.

Claims (12)

A composition for treating a nicotine responsive psychiatric disorder, comprising a nicotine antagonist. The nicotine responsive psychiatric disorder is Tourette syndrome, schizophrenia, mania, manic depression, attention deficit hyperactivity disorder, outrage, obsessive compulsive disorder, or a combination thereof. Composition. A composition for treating a nicotine responsive motility disorder, comprising a nicotine antagonist. 4. The composition of claim 3, wherein the nicotine responsive motility disorder is selected from the group consisting of Tourette's syndrome, essential tremor, half body muscle tone abnormalities, and late movement disorders. A composition for treating Tourette's syndrome, comprising a nicotine antagonist. A composition for treating attention deficit hyperactivity disorder, comprising a nicotine antagonist. To treat signs and symptoms that include nicotine antagonists, including distraction, hyperactivity, tremor, obsessive compulsive behavior, mania and mood swings, motility due to Tourette's syndrome and phonetic tics, or combinations thereof Composition. The composition according to any one of claims 1 to 7, wherein the nicotine antagonist is mecamylamine, a stereoisomer of mecamylamine, or an analog of mecamylamine. The composition according to any one of claims 1 to 7, wherein the nicotine antagonist is mecamylamine. The composition according to any one of claims 1 to 9, which is administered in combination with a neuroleptic agent. 11. The composition of claim 10, wherein the neuroleptic agent is selected from the group consisting of haloperidol, pimozide, fluphenazine and risperidone. 8. A composition according to any one of claims 1 to 5 and 7, wherein the nicotine antagonist is administered in an amount that reduces the frequency and severity of tics in the patient.

Images